AACR19 day 3 update: PARP inhibitors and much more

Written by Jade Parker, Senior Editor

Today at our booth

The third day was one of the most exciting days of the AACR conference for the Oncology Central team as we eagerly waited to discover all the data from the plenary session. We have collated our highlights, let us know your thoughts in the comments below or on social media.

Remember you can find us at booth #4438, or follow our Twitter updates @OncologyCentral.

Video highlights

 

Today’s news

Rucaparib produces clinical response in certain pancreatic cancer patients

Maintenance therapy with the PARP inhibitor rucaparib (Rubraca®) has produced clinical responses amongst a subgroup of patients with advanced BRCA- or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy.

Find out further details.

Esophageal cancers – combining virotherapy and radiotherapy shows early promise

Results from a Phase I clinical trial have indicated that a combination of virotherapy and radiotherapy results in a high response rate in esophageal cancer patients who may be unable to undergo more invasive treatments.

Read the full story.

Surgery associated with increased survival in HER2+ Stage IV breast cancer patients

Results from a Phase lll clinical trial, assessing the effectiveness of a new targeted drug, taselisib, have demonstrated promising results against advanced breast cancer when combined with standard hormone therapy fulvestrant (Faslodex®).

Discover further details.

Adults at high-risk of HIV less likely to be vaccinated against HPV

Adults at high risk of HIV infection were less likely than the general population to be vaccinated against HPV, which can cause anal and cervical cancer.

Read more.

Worldwide study of prostate cancer shows incidence and mortality in decline

Prostate cancer incidence and mortality rates are decreasing or stabilizing in most parts of the world, with the United States recording the biggest drop in incidence.

Read the full story.

Study points the finger at a common SNP for stroke risk in cancer survivors

Researchers have demonstrated that a common SNP is associated with an increased risk of stroke in childhood cancer survivors treated with cranial radiation therapy.

Find out more.

Best of social media #AACR19